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Abstract 
 
DietCompLyf is a multi-centre prospective study designed to investigate associations between phytoestrogens - 
naturally occurring plant compounds with oestrogenic properties - and other diet and lifestyle factors with breast 
cancer recurrence and survival. 3159 women with grade I-III breast cancer were recruited 9-15 months post-
diagnosis from 56 UK hospitals. Detailed information on clinico-pathological, diet, lifestyle and quality of life is 
collected annually up to 5 years. Biological samples have also been collected as a resource for subsequent 
evaluation. The characteristics of the patients and associations between pre-diagnosis intake of phytoestrogens 
(isoflavones and lignans; assessed using the EPIC-Norfolk UK 130 question food frequency questionnaire) and 
breast cancer (i) risk factors and (ii) prognostic factors are described for 1797 women who had complete data for 
all covariates and phytoestrogens of interest. Isoflavone intakes were higher in the patients who were younger at 
diagnosis, in the non-smokers, those who had breast-fed and those who took supplements. Lignan intakes were 
higher in patients with a higher age at diagnosis, in ex-smokers, those who had breast-fed, who took 
supplements, had a lower BMI at diagnosis, lower age at menarche and were nulliparous. No significant 
associations between pre-diagnosis phytoestrogen intake and factors associated with improved breast cancer 
prognosis were observed. The potential for further exploration of the relationship between phytoestrogens and 
breast cancer recurrence and survival, and for the establishment of evidence to improve dietary and lifestyle 
advice offered to patients following breast cancer diagnosis using DietCompLyf data is discussed.  
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1. Introduction 
Age-standardised incidence rates for female breast cancer in Northern Europe exceed those for Eastern Asia, 
with 84 and 25 cases reported per 100 000 population respectively [1]. Migration studies have shown that the 
risk of developing breast cancer increases to approximately that of the host nation within a few generations [2]. 
Considerable effort has been expended to identify dietary, lifestyle and environmental factors that may 
contribute to these geographic differences in breast cancer risk.  
 
Phytoestrogens are naturally occurring plant compounds capable of eliciting oestrogen-like properties through 
binding to oestrogen receptors (ER) and other mechanisms. Intakes vary significantly between Eastern and 
Western diets. Eastern diets typically include soy-based foods which are rich in isoflavones, one of the main 
groups of phytoestrogens whilst Western diets more typically obtain isoflavones from legumes, coffee, nuts, 
bread and soya milk [3]. Lignans are the most common phytoestrogens found in UK foods (e.g., beverages, 
cereals, cruciferous vegetables and some fruits), yet isoflavones account for the greatest phytoestrogen intakes 
due to the use of soya in bread production [4]. 
 
The biological complexity of phytoestrogens is well described [5]. Understanding the in vivo effects of 
phytoestrogens is complicated by different forms and quantities of intake and individual metabolic differences. 
Despite these difficulties, several studies have investigated the relationship between phytoestrogen intake and 
breast cancer risk. Research findings are not yet conclusive; however early evidence suggests protective 
relationships, to varying extents and using different markers (diet, urine and serum concentrations) in Western 
[6] and Eastern populations [7]. The role of phytoestrogens on breast cancer recurrence rates and overall survival 
is less well studied. Early results show inverse associations between phytoestrogen intake and breast cancer 
recurrence [8] and mortality [9]. Biomarkers of phytoestrogen metabolism are associated with improved survival 
[10]. However more studies are needed to investigate the link between phytoestrogens and breast cancer 
recurrence as conflicting data continues to emerge [11]. 
 
2. Aims 
The DietCompLyf study has been established to examine the relationship between dietary intake of lignans and 
isoflavones and breast cancer recurrence (primary outcome) and survival in pre- and post- menopausal women in 
the UK. Data on acknowledged risk factors has been collected alongside information on more novel factors 
which currently have suggestive evidence of an association with recurrent breast cancer. We outline here the 
methods used within the DietCompLyf study, describe the cohort and the evaluation procedures used to estimate 
phytoestrogen intake levels prior to diagnosis collected using the EPIC-Norfolk 130 question food frequency 
questionnaire (FFQ). Considering the relationship between this and other known prognostic factors for breast 
cancer, these results are used to inform the planned later analyses. 
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3. Study design 
 
3.1. DietCompLyf - overview 
 
DietCompLyf is a prospective, observational study based in the UK. With ethical approval from the University 
College London Hospitals Research Ethics Committee, recruitment was rolled out in two phases. The first wave 
recruited 582 patients from 4 hospitals (Feb 1997 – Feb 2005). In 2004, the study was adopted by the National 
Cancer Research Network and the protocol was expanded to obtain clinical information over a longer duration 
and from an increased number of centres. The second phase recruited 2808 patients (Dec 2004 – Aug 2010) from 
56 NHS centres (Fig. 1). Recruitment rates are shown in Fig. 1. 3390 breast cancer patients were enrolled, of 
whom 3159 (93.2%) fulfilled all inclusion criteria and were considered evaluable for analysis of phytoestrogen 
intake levels (Fig. 2). Poor compliance with the 24 h urine collections in the initial protocol (52.3% completed a 
24 h sample) and evidence of comparability between levels of enterolactone in spot and 24 h urine samples [12] 
prompted a protocol amendment to collection of spot samples.  
 
3.2. Recruitment and follow-up 
 
Female patients were invited to participate if they had a histologically confirmed invasive primary breast cancer 
(grade I to III), were 9 to 15 months post diagnosis (after completion of active breast cancer treatment) and were 
up to and including 75 years of age. Exclusion criteria were: previous cancer (except basal cell carcinoma); 
concomitant primary cancer; bilateral cancer of the breast; cognitive impairment; psychological difficulties; or a 
poor understanding of English. All patients provided written consent agreeing to participate in the study.  
 
Recruitment and follow-up visits were designed to run in parallel with the patients’ clinical follow-up schedule. 
Patients were assessed every 6 months for 2 years in the first recruitment wave and annually for 4 years when 
recruitment was extended. Clinico-pathological details and treatment was recorded at recruitment and follow-up 
(Supplementary Table S1). At each visit, blood and urine samples were collected and questionnaires were 
completed (Table 1). A summary of the information collected is illustrated in Fig. 3. A record was made if a 
course of antibiotics had been taken in the previous 3 months as this could disrupt the intestinal microflora and 
affect phytoestrogen metabolism [13]. Data quality checks were initiated at the coordinating centre and 
anomalies were checked and corrected in consultation with each centre. Data entry checks were performed on 
5% of baseline data (median transcription errors 0.68%). Centre staff reported details of a new primary cancer, 
breast cancer recurrence, metastasis, withdrawal, if patients had become lost to follow up or had died. Updates 
on participant mortality were provided through the NHS Information Centre. Final follow-up data is expected to 
be collected by the end of 2015. 
 
3.3. Sample collection 
 
At recruitment, 6 ml of blood was collected in a Vacutainer containing EDTA (BD Bioscience) for plasma and 
12 ml of blood was collected for serum at each study visit. All blood was allowed to stand for at least one hour 
and centrifuged at approximately 1200 xg for 15 min and 0.5 ml of the supernatant was aliquoted. Buffy coats 
were removed and stored in a DNase / RNase-free cryovial (Nalgene) for future DNA extraction. Urine samples 
were centrifuged at approximately 1200 xg for 15 min and ten aliquots of 1.25 ml were stored frozen. Time of 
blood and urine collection, freezing and centrifugation were recorded. Samples were temporarily stored at 
centres at temperatures between -20°C and -80°C. After transfer to the coordinating centre, all samples were 
catalogued and stored at -80°C.  
 
3.4. Questionnaires 
 
A range of questionnaires, validated where possible, to evaluate diet, lifestyle, general health and quality of life 
were given to patients.  
 
A lifestyle questionnaire was completed at recruitment. This provided information on ethnicity, occupation, 
education, family history of breast cancer, reproductive history, physical activity, alcohol use, smoking and 
CAM. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 v2.0 quality of 
life assessment [14] was used. A follow-up questionnaire comprising a condensed version of the lifestyle 
questionnaire assessed changes in lifestyle annually. A general health questionnaire (GHQ-12) was completed at 
every study visit [15]. 
 
Diet was evaluated annually using the 130 question EPIC-Norfolk FFQ (CAMB/PQ/6/1205) [16]. Patients 
reporting dietary changes post-diagnosis completed a retrospective FFQ at recruitment. The Compositional 
Analyses from Frequency Estimates (CAFÉ) program was used to estimate nutrient intake [17] from the FFQs 
following quality control checks on ≥10% of entered questionnaires (Adetiq, East Sussex). Individuals with ≥10 
missing responses and those in the extreme 0.5% of energy intake: basal metabolic rate ratios were excluded 
[17]. At year 2 (and 4 in the second recruitment wave), a more detailed 7-day food diary was also completed 
[18]. 
 
3.5. Sample size calculation 
 
Using the primary outcome – recurrence free survival – for individual or combined phytoestrogens, sample size 
calculations were based on 20 events per covariate for the primary analysis. The number of patients required to 
observe at least 200 events was estimated using the expected event rates observed from the ATAC [19], NEAT 
[20] and Early Breast Cancer Trialist’ Collaborative Group [21] studies where 5-year survival was 70-86%. A 
sample size target of 2300-3000 was set after adjustment for recruitment approximately 1 year post-diagnosis; 
missing or non-analysable urine samples; missing data for pre-specified prognostic covariates; patients lost to 
follow-up, addition of further covariates and taking into account improvements in breast cancer survival rates.  
 
3.6. Assessment of phytoestrogen consumption and breast cancer prognostic factors 
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The association between pre-diagnosis phytoestrogen intake and breast cancer risk/prognostic factors was 
assessed for 1797 patients who had complete data for all covariates and phytoestrogens of interest (Table 2). Log 
transformed phytoestrogen intake estimates were used in the univariate regression models to identify factors for 
inclusion in the final multivariate model, using a backward stepwise selection model; computed using STATA 
version 11 (Stata/IC 11.0, Texas, USA, StataCorp LP©). 
 
Intakes of phytoestrogen-containing food groups were considered in age tertiles and by dietary preference 
(vegetarian, fish, meat or meat and fish diet). Foods were grouped as: meat; fish; bread and savoury biscuits; 
cereals; potatoes, rice and pasta; dairy products and fats; sweets and snacks; soups, sauces and spreads; non-
alcoholic drinks; alcoholic drinks; fruit; vegetables; beans, lentils, nuts and peas; tofu, soya meat, textured 
vegetable protein and vegeburgers. Daily portions consumed per food group were calculated using a previously 
published method [17]. Differences between age and dietary preference groups were assessed using one-way 
ANOVA with a post-hoc Bonferroni adjustment for multiple testing in patients with evaluable data. Number of 
portions consumed between the lower and upper age quartile was assessed using an independent samples t-test. 
Data was analysed using SPSS version 19 (SPSS Inc., Chicago, IL, USA, IBM Company). 
 
This evaluation has allowed us to determine the patterns of phytoestrogen consumption across the DietCompLyf 
cohort to assess the heterogeneity of consumption levels across all pre/peri and post-menopausal breast cancer 
patients. 
 
 
 
4. Data reported at baseline 
 
4.1. Recruitment and return rate 
 
Flow chart of patient recruitment and their contribution at the various time-points up to where the visits are 
complete (up to year 3 post-diagnosis) is presented in Fig. 2. The return rate for the lifestyle questionnaire at 
recruitment was 94.7% and follow-up lifestyle questionnaires from active patients have remained above 80% 
throughout the study. Almost all the patients contributed biological samples at recruitment: 98.6% and 93.5% for 
urine and blood, respectively.  
 
4.2. Baseline characteristics 
 
The mean time from diagnosis to recruitment for the 3159 evaluable patients was 12.4 ± 1.75 months. The 
majority of patients were post-menopausal (64.9%), had a grade II (45.9%), ER positive (81.6%) tumour, less 
than 20 mm diameter (49.9%), and were lymph node negative (61.9%) (Table 2). At the time of writing 
(26/02/13), the mean follow-up on the study was 38.5 ± 15.7 months from recruitment (50.8 ± 15.8 months from 
breast cancer diagnosis). 
 
4.3. Phytoestrogen intake  
 
Pre-diagnosis phytoestrogen intakes in the analysed subgroup were similar to that of the whole cohort (Table 
3a). The lignan, secoisolariciresinol was consumed in the greatest quantity, with genistein the predominant 
isoflavone consumed. Phytoestrogen consumption showed a skewed distribution. In the sub-group analysis, the 
lignan, secoisolariciresinol was consumed in the greatest quantity (281.0, 276.1 – 285.9 µg/day), with genistein 
the predominant isoflavone consumed (267.6, 254.6 – 281.2 µg/day). Consumption of isoflavones varied a 1000 
fold, with an average consumption of 484.3 (462.2 – 507.4) µg/day and consumption of lignans varied 100 fold 
with an average of 322.7 (317.3 – 328.1) µg/day. 
 
Patients with a vegetarian or fish-only diet consumed significantly more isoflavones than those with a meat 
containing diet. Meat eaters had a significantly lower intake of total lignans compared to those who had a 
vegetarian or a meat and fish diet but not a fish only diet (Table 3b). The intakes of the isoflavones genistein, 
daidzein and glycitein correlated with each other (R>0.96, p<0.001), and to a lesser extent with the lignan 
secoisolariciresinol (R 0.20 – 0.30, p<0.001) (Table 3c). 
 
Univariate analyses (Supplementary Table S2) showed genistein, daidzein, glycitein and secoisolariciresinol 
were significantly associated with every variable tested (p<0.001). However, multivariate analyses showed no 
association with the pre-diagnosis phytoestrogen intake and tumour characteristics (data not shown; p>0.05). 
Intakes of genistein, daidzein and glycitein were significantly higher in patients who were younger at the time of 
diagnosis, those who took supplements, non-smokers and those who had breast fed (p<0.05) (Table 4). Genistein 
intake was also significantly higher in patients who had never taken hormone replacement therapy (p<0.05). 
Consumption of secoisolariciresinol pre-diagnosis was higher in older patients, those who reported supplement 
usage, ex-smokers, those who had breast fed, nulliparous women, those with a lower BMI at diagnosis and lower 
age at menarche (p<0.05).  
 
Differences in phytoestrogen consumption were further investigated by grouping the patients into tertiles, 
according to age at diagnosis (mean ages: 43.4, 54.0, 64.2 years) (Table 5). Significantly more lignans were 
consumed by patients in the middle and upper age tertiles compared to the lower age tertile (p<0.01). More 
isoflavones were consumed by the lower and middle age tertiles than the upper age tertile (p<0.01). This 
variance is explained by the food groups consumed by these women. Breads, cereals, fish, soups, sauces and 
spreads, fruit and vegetables were preferred by older women and potatoes, rice and pasta, sweets and snacks, 
tofu/soya meat, by younger women. Other food groups: dairy, non-alcoholic drinks, alcoholic drinks, beans and 
lentils, were consumed in similar proportions by all age groups. There were significantly more vegetarian 
women in the younger compared to the older participant age group (tertile 1: 4.0%, tertile 3: 0.8%) (χ2 = 12.4, 
p<0.01). 
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5. Expected outcomes of DietCompLyf 
 
DietCompLyf has been established to evaluate associations between phytoestrogen intake levels and breast 
cancer recurrence (primary outcome) and survival. To our knowledge, this is the largest, most detailed study of 
breast cancer patients’ diet and lifestyle in the UK. The initial assessment of the reported phytoestrogen 
consumption levels show participants have a lower phytoestrogen intake than those observed in Asian 
populations [22], but were consistent with those of other UK populations [23]. Multicollinearity was evident 
with intakes of individual isoflavones genistein, daidzein and glycitein (R>0.9), showing that different 
isoflavones are found and/or eaten in foods at the same time. Isoflavones were consumed in a greater quantity 
than lignans, as previously shown in a UK population [24]. 
 
Food preferences which impacted total isoflavone and lignan intake levels were identifiable with age. Older 
women tended to favour lignan-containing, younger women isoflavone-containing, foods. The increased intake 
of isoflavones in younger women agrees with other UK data [3] and higher lignan consumption in older women 
has also been reported elsewhere [25]. However, the differences in lignan consumption across the different age 
groups has not (to our knowledge) previously been reported for UK breast cancer patients. Food group analyses 
attributed the isoflavone intake in the DietCompLyf population to tofu/soya meat consumption. Vegetarianism 
alone did not account for disparities in tofu/soya meal consumption; therefore it is hypothesized that this dietary 
change may reflect recent changes in health, diet and food availability and/or a combination thereof. It was 
expected that bread and soya milk consumption would provide the majority of isoflavones consumed in a UK 
diet [3], yet only 1% of the patients in this subset reportedly drank soya milk. The heterogeneity (bread 
containing soy and linseed for example being contained in the same group as standard brown bread; genistein 
contents of 6,807 and 246 µg/100g respectively) was not controlled for [26].  
 
In other studies phytoestrogens have been shown to relate to breast cancer characteristics at diagnosis, for 
example an increase in dietary lignans [27] and isoflavones [28] have been found to be associated with ER 
positive tumours. Higher lignan consumption has been related to a reduction in lymphovascular invasion, and 
smaller tumour size [29], although the Australian population studied had an order of magnitude higher lignan 
intake levels compared with the DietCompLyf cohort (between 1,640 and 2,260 µg/d from an FFQ). Similarly, 
Buck et al., [10] reported that post-menopausal breast cancer patients with higher levels of serum enterolactone 
had smaller tumours of a lower tumour grade and were more likely to be hormone receptor positive. In the 
DietCompLyf cohort total phytoestrogen intake was associated with tumour characteristics (tumour grade, size, 
lymph node status, ER status, and vascular invasion) at diagnosis in univariate regression models (effects 
attenuated in multivariate models). In addition, there were significant associations between each of the dietary 
phytoestrogens measured and risk factors for breast cancer: age at diagnosis, age at menarche, breast feeding and 
parity. Phytoestrogen levels were also associated with lower BMI at diagnosis, consistent with either higher 
consumption of fibre containing foods and/or lower consumption of fatty foods.  
 
Supplement use can potentially affect an individual’s overall phytoestrogen consumption levels. An interim 
analysis of patients recruited onto DietCompLyf identified that 56% of patients were supplement users pre-
diagnosis [30]. With recruitment now complete estimates using data from all the participants who provided a 
pre-diagnosis FFQ highlights a reduced proportion of supplement users (47%). The underlying reasons for this 
difference is not clear, but – in light of adding centres to the study – it is expected that geographical, 
socioeconomic, educational status and so on may explain this variance, but this will require further investigation 
to elucidate. The difficulties in determining phytoestrogen levels in supplements led to this factor being assessed 
as a binary variable, accordingly, only a partial exploration of supplement usage has been undertaken. A 
database incorporating phytoestrogen levels in supplements is under construction as part of a longer-term 
research endeavour. The absence of an association between phytoestrogen consumption and prognostic factors 
for breast cancer reported here may reflect the paucity of information on intake of phytoestrogens from 
supplements and it is likely that phytoestrogen consumption has been somewhat underestimated. The availability 
of serum/urine samples from individual patients however will allow an exploration of supplement usage and 
phytoestrogen levels in later studies. 
 
To our knowledge, DietCompLyf is the largest, most comprehensive evaluation of diet, phytoestrogen intake and 
lifestyle in women diagnosed with breast cancer across the UK. Dietary intake estimates are complemented by 
analyses of serum and urinary phytoestrogen levels; the cohort includes pre, peri and postmenopausal patients, 
and data are sampled over repeated time points. The continued reporting of recurrence and mortality rates will 
allow the progression of the disease to be mapped with respect to each of these factors. The DietCompLyf study 
will therefore provide an opportunity for strengthening of current scientific evidence to establish dietary 
recommendations for individuals diagnosed with breast cancer, which could lead to reduced recurrence rates. 
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Figure captions 
 
Fig. 1 DietCompLyf recruitment. (a) Map showing the distribution of DietCompLyf centres across the UK. (b) 
Chart shows the rate of recruitment onto DietCompLyf displaying the number of participants (□) and the number 
of recruiting centres (   ). Data is given for August of each year.  
 
Fig. 2 Consort diagram for patients eligible on the DietCompLyf study. The total number of returned 
questionnaires and samples collected are shown for the completed phases of the study.  
 
Fig. 3 The design of the DietCompLyf study showing the multi-factorial nature of breast cancer and the diverse 
information collected in the DietCompLyf study is shown. The instrument used to capture the information is 
displayed in bold. 
 
Supplementary data: 
Supplementary data are available at Maturitas online 
 
Conflict of interest: None declared. 
 
Funding: 
This work was funded by Against Breast Cancer (Registered Charity Number 1121258). 
 
Acknowledgements: 
We would like to thank Amber Gibney and Sally Hughes for data checking, the MRC CNC in Cambridge for 
their assistance with the FFQ and 7-day food diary processing and the expertise provided by the late Shelia 
Bingham of the MRC centre and the use of the FFQ and 7-day food diary.  
 
 
We would like to thank all the DietCompLyf study patients and the following Principal Investigators funded 
through the National Cancer Research Network: Dr J Abraham, Mrs M Adams, Dr M Ah-See, Dr S Ahmed, Dr 
W Appel, Dr L Barraclough, Prof P Barrett-Lee, Mr R Bonomi, Mrs S Breakspear, Mrs S Bulley, Mrs J Clarke, 
Dr A Clayton, Prof N Davidson, Ms J Dodge, Mr H Dymond, Dr H Eldeeb, Prof O Eremin, Miss A Evans, Dr D 
Fermont, Mr C Gateley, Mr I Gouldbourne, Mr M Graham, Prof R Grieve, Mr D Hadjiminas, Dr M Hall, Dr A 
Hong, Dr S Houston, Dr R Hunter, Mrs S Jones, Mr M Keshgar, Mr I Laidlaw, Mrs A Lannigan, Dr B Lavery, 
Dr G Mazdai, Dr K McAdam, Dr J McAleer, Dr M Napier, Dr C Palmer, Dr U Panwar, Mrs J Pascoe, Mr A 
Paterson, Mrs C Reed, Dr P Riddle, Mr C Rogers, Dr A Sahu, Dr E Sawyer, Dr N Shah, Dr M Shere, Dr E 
Sherwin, Mr M Sibbering, Dr R Simcock, Dr D Spooner, Dr K Stepp, Dr A Stevens, Dr J Stewart, Ms H 
Sweetland, Prof S Tahir, Dr R Thomas, Prof A Thompson, Dr S Upadhyay, Mr R Visvanathan, Miss B Weber, 
Mrs B Williams-Yesson, Mr A Wilson, Prof J Yarnold, Mrs T Young. 
 
 
References 
[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 
2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917. 
[2] Liu L, Zhang J, Wu AH, Pike MC, Deapen D. Invasive breast cancer incidence trends by detailed 
race/ethnicity and age. Int J Cancer 2012;130:395-404. 
[3] Mulligan AA, Welch AA, McTaggart AA, Bhaniani A, Bingham SA. Intakes and sources of soya foods and 
isoflavones in a UK population cohort study (EPIC-Norfolk). Eur J Clin Nutr 2007;61:248-54. 
[4] Ward HA, Kuhnle GG. Phytoestrogen consumption and association with breast, prostate and colorectal 
cancer in EPIC Norfolk. Arch Biochem Biophys 2010;501:170-5. 
[5] Velentzis LS, Woodside JV, Cantwell MM, Leathem AJ, Keshtgar MR. Do phytoestrogens reduce the risk of 
breast cancer and breast cancer recurrence? What clinicians need to know. Eur J Cancer 2008;44:1799-806. 
[6] Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. 
Lancet 1997;350:990-4. 
[7] Dai Q, Franke AA, Jin F, Shu XO, Hebert JR, Custer LJ, et al. Urinary excretion of phytoestrogens and risk 
of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 2002;11:815-21. 
[8] Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, et al. Soy food intake and breast cancer survival. JAMA 
2009;302:2437-43. 
[9] McCann SE, Thompson LU, Nie J, Dorn J, Trevisan M, Shields PG, et al. Dietary lignan intakes in relation 
to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) 
Study. Breast Cancer Res Treat 2010;122:229-35. 
[10] Buck K, Vrieling A, Zaineddin AK, Becker S, Husing A, Kaaks R, et al. Serum enterolactone and prognosis 
of postmenopausal breast cancer. J Clin Oncol 2011;29:3730-8. 
[11] Woo HD, Park KS, Ro J, Kim J. Differential influence of dietary soy intake on the risk of breast cancer 
recurrence related to HER2 status. Nutr Cancer 2012;64:198-205. 
[12] Stumpf K, Adlercreutz H. Short-term variations in enterolactone in serum, 24-hour urine, and spot urine and 
relationship with enterolactone concentrations. Clin Chem 2003;49:178-81. 
[13] Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Adlercreutz H. Use of oral antimicrobials 
decreases serum enterolactone concentration. Am J Epidemiol 2002;155:472-7. 
[14] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization 
for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical 
trials in oncology. J Natl Cancer Inst 1993;85:365-76. 
[15] Goldberg DP, Williams P. A user's guide to the General Health Questionnaire. London: NFER-Nelson; 
1988. 
[16] Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, et al. Comparison of dietary assessment 
methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and 
estimated-diet records. Br J Nutr 1994;72:619-43. 
[17] Welch AA, Luben R, Khaw KT, Bingham SA. The CAFE computer program for nutritional analysis of the 
EPIC-Norfolk food frequency questionnaire and identification of extreme nutrient values. J Hum Nutr Diet 
2005;18:99-116. 
12 
 
[18] Welch AA, McTaggart A, Mulligan AA, Luben R, Walker N, Khaw KT, et al. DINER (Data Into Nutrients 
for Epidemiological Research) - a new data-entry program for nutritional analysis in the EPIC-Norfolk cohort 
and the 7-day diary method. Public Health Nutr 2001;4:1253-65. 
[19] Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as 
adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 
2008;9:45-53. 
[20] Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and cyclophosphamide, 
methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355:1851-62. 
[21] Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early 
breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-
717. 
[22] Chen Z, Zheng W, Custer LJ, Dai Q, Shu XO, Jin F, et al. Usual dietary consumption of soy foods and its 
correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in 
Shanghai. Nutr Cancer 1999;33:82-7. 
[23] Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting NP, et al. Phytoestrogen concentrations in 
serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in 
European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev 
2004;13:698-708. 
[24] Mulligan AA, Kuhnle GG, Lentjes MA, van Scheltinga V, Powell NA, McTaggart A, et al. Intakes and 
sources of isoflavones, lignans, enterolignans, coumestrol and soya-containing foods in the Norfolk arm of the 
European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk), from 7 d food diaries, using a 
newly updated database. Public Health Nutr 2012;1-9. Epub ahead of print. 
[25] Milder IE, Feskens EJ, Arts IC, Bueno de Mesquita HB, Hollman PC, Kromhout D. Intake of the plant 
lignans secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in Dutch men and women. J Nutr 
2005;135:1202-7. 
[26] Kuhnle GG, Dell'aquila C, Aspinall SM, Runswick SA, Mulligan AA, Bingham SA. Phytoestrogen content 
of cereals and cereal-based foods consumed in the UK. Nutr Cancer 2009;61:302-9. 
[27] McCann SE, Hootman KC, Weaver AM, Thompson LU, Morrison C, Hwang H, et al. Dietary intakes of 
total and specific lignans are associated with clinical breast tumor characteristics. J Nutr 2012;142:91-8. 
[28] Zhang M, Liu X, Holman CD. Effect of dietary intake of isoflavones on the estrogen and progesterone 
receptor status of breast cancer. Nutr Cancer 2010;62:765-73. 
[29] Ha TC, Lyons-Wall PM, Moore DE, Tattam BN, Boyages J, Ung OA, et al. Phytoestrogens and indicators 
of breast cancer prognosis. Nutr Cancer 2006;56:3-10. 
[30] Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, et al. Significant changes 
in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res 
Treat 2011;128:473-82. 
 
 
Competing Interests 
 
The authors declare no conflict of interest 
Competing interests Maturitas Swann
Funding Information 
 
The work in this article was supported by the charity Against Breast Cancer (Registered Charity 
Number 1121258). 
The authors received no funding for this article. 
 
 
Funding information Maturitas Swann
TABLES 
 
 
 
Table 1 The schedule of participant follow up and contribution at each study visit.  
 
 
 Time after diagnosis (years) 
 1 1.5 2 3 4 5 6 
Spot urine 
10 x 
1.25 ml 
10 x 
1.25 ml
a
 
10 x 
1.25 ml* 
10 x 
1.25 ml
b
 
10 x 
1.25 ml
b
 
10 x 
1.25 ml
b
 
 
 
 
24 h urine  
 
 
2 x 
20 ml*
a
 
 
 
  
 
 
Serum 
6 x 
0.5 ml 
6 x 
0.5 ml
a
 
6 x 
0.5 ml 
6 x 
0.5 ml
b
 
6 x 
0.5 ml
b
 
6 x 
0.5 ml
b
 
 
 
 
Plasma 
3 x 
0.5 ml 
3 x 
0.5 ml
a
 
3 x 
0.5 ml
a
 
 
 
  
 
 
Buffy coat 1 1
a
 1
a
    
 
 
Lifestyle questionnaire   b    a 
FFQ † a     a 
GHQ  a     a 
7-day food diary     b   
 
 
a
Recruitment 1997-2004, 
b
recruitment 2004-2010 only. *Either a 24 h or a spot urine was collected during first 
wave of recruitment. 
†
Two FFQs were filled in at recruitment to reflect diet pre- and post-diagnosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table
Table 2 Descriptive covariates, showing the number of evaluable participants (n=3159) and those 
used in the sub-group (n=1797) analysis. Age at first full pregnancy was omitted from the analysis 
due to the association with parity. 
 
Variable 
Evaluable 
participants 
n=3159 
n (%) 
Sub-group 
 
n=1797 
n (%) 
 
Variable 
Evaluable 
participants 
n=3159 
n (%) 
Sub-group 
 
n=1797 
n (%) 
Age at diagnosis 
mean ± SD 
n 
54.4 ± 9.7 
  
3159 (100.0) 
53.9 ± 9.3 
  
1797 (100.0) 
 Age at menarche  
mean ± SD 
n 
12.7 ± 1.6 
 
 2646 (83.8) 
12.7 ± 1.5 
  
1797 (100.0) 
   
 BMI at diagnosis (Kg/m
2
) 
mean ± SD 
N 
26.8 ± 5.3 
  
3077 (97.4) 
26.6 ± 5.2 
 
1797 (100.0) 
Tumour grade    Menopausal status   
Grade I  500 (15.8) 294 (16.4)  Pre  609 (19.3) 343 (19.1) 
Grade II  1451 (45.9) 823 (45.8)  Peri  464 (14.7) 301 (16.8) 
Grade III 1176 (37.2) 680 (37.8)  Post  2049 (64.9) 1153 (64.2) 
Missing  32 (1.0) -  Missing  37 (1.2) - 
Tumour size    Smoking   
<20 mm  1575 (49.9) 916 (51.0)  Never  1531 (48.5) 906 (50.4) 
≥20 mm  1285 (40.7) 746 (41.5)  Current  294 (9.3) 168 (9.3) 
Multifocal  234 (7.4) 135 (7.5)  Ex-smoker  1152 (36.5) 723 (40.2) 
Missing  65 (2.1) -  Missing  182 (5.8) - 
Lymph node status    Parity   
Negative  1956 (61.9) 1083 (60.3)  0  360 (11.4) 236 (13.1) 
Positive  1190 (37.7) 714 (39.7)  1+  2181 (69.0) 1561 (86.9) 
Missing  13 (0.4) -  Missing  618 (19.6) - 
Histology    Age at first full pregnancy   
Ductal  2492 (78.9) 1428 (79.5)  No pregnancy  360 (11.4) 236 (13.1) 
Ducto-lobular  102 (3.2) 58 (3.2)  ≤ 20 years  457 (14.5) 326 (18.1) 
Lobular  351 (11.1) 198 (11.0)  20-30 years  1357 (43.0) 970 (54.0) 
Other 193 (6.1) 113 (6.3)  > 30 years  367 (11.6) 265 (14.7) 
Missing  21 (0.7) -  Missing  618 (19.6) - 
ER    Breast fed   
Negative  551 (17.4) 313 (17.4)  No  1242 (39.3) 752 (41.8) 
Positive  2578 (81.6) 1484 (82.6)  Yes  1407 (44.5) 1045 (58.2) 
No tested  30 (0.9) -  Missing  510 (16.1) - 
Vascular invasion    Oral contraceptive use   
No  1815 (57.5) 1228 (68.3)  No  416 (13.2) 273 (15.2) 
Yes  764 (24.2) 569 (31.7)  Yes  2101 (66.5) 1524 (84.8) 
Missing  580 (18.4) -  Missing  642 (20.3) - 
Supplement use    HRT   
No  1406 (44.5) 952 (53.0)  No  1647 (52.1) 1151 (64.1) 
Yes  1248 (39.5) 845 (47.0)  Yes  973 (30.8) 646 (35.9) 
Missing  505 (16.0) -  Missing  539 (17.1) - 
 
Abbreviations: ER, oestrogen receptor; HRT, hormone replacement therapy; SD, standard deviation.  
Table 3 Average dietary intake of phytoestrogens from FFQs for (a) the whole cohort with FFQ data 
(n=2582) and evaluable participants used in sub-group analysis (n=1797). (b) Individuals in the sub-
group are categorised by diet type. (c) Pearson correlation coefficients between phytoestrogen intake 
for evaluable participants with complete data (n=1797). 
†
Untransformed data. The geometric mean is 
the back-transformed mean of the log transformed data. All correlations were significant p<0.001. 
Total isoflavones includes genistein, daidzein, glycitein, biochanin A, formononetin. Total lignans 
includes secoisolariciresinol, shonanin, and matairesinol. Total phytoestrogens includes genistein, 
daidzein, glycitein, biochanin A, formononetin, secoisolariciresinol, shonanin, matairesinol, 
coumestrol, enterolactone, equol, enterodiol.  
 
a 
 
 
 
Total cohort with evaluable FFQ data 
n=2582 
Sub-group n=1797 
 
Geometric mean  
(95% CI) 
Range
†
 
µg/day 
Geometric mean  
(95% CI) 
Range
†
 
µg/day 
Genistein 266.3   (255.2 – 277.8) 14.8 – 31 025.7 267.6   (254.6 – 281.2) 19.7 – 29 754.4 
Daidzein 153.0   (147.1 – 159.2) 5.9 – 13 456.4 153.8   (146.8 – 161.1) 9.9 – 13 351.0 
Glycitein 32.5     (31.3 – 33.7) 2.6 – 2280.3 32.7     (31.3 – 34.1) 2.7 – 1623.0 
Secoisolariciresinol 276.1   (272.0 – 280.3) 54.2 – 1105.5 281.0   (276.1 – 285.9) 75.1 – 1105.5 
Total isoflavones 482.2   (463.4 – 501.8) 39.7 – 46 415.5 484.3   (462.2 – 507.4) 43.5 – 44 634.1 
Total lignans 317.3   (312.8 – 321.8) 60.2 – 1178.2 322.7   (317.3 – 328.1) 84.5 – 1178.2 
Total phytoestrogens 918.8   (891.7 – 946.7) 156.4 – 46 819.5 924.2   (892.5 – 957.1) 219.5 – 44 940.0 
 
 
 
 
b 
 
Diet n 
Total isoflavones 
Geometric mean (95% CI) 
Total lignans 
Geometric mean (95% CI) 
Total phytoestrogens 
Geometric mean (95% CI) 
Vegetarian 47 2788.3 (1829.9 – 4248.5) 360.7 (328.7 – 395.9) 3607.3  (2569.4 – 5064.3) 
Fish only 44 2074.7 (1358.7 – 3168.2) 329.8 (293.7 – 370.4) 2775.2  (1987.7 – 3874.9) 
Meat only 59 350.4 (269.4 – 455.7) 278.9 (253.6 – 306.7) 721.5  (594.0 – 876.4) 
Meat and fish 1647 448.3 (429.2 – 468.2) 323.1  (317.6 – 328.8) 871.0  (843.4 – 899.4) 
 
 
 
 
c 
All p-values <0.001 
 
Abbreviations: CI, confidence interval.
 
Log 
genistein 
Log 
daidzein 
Log 
glycitein 
Log secoiso-
lariciresinol 
Log total 
isoflavones 
Log total 
lignans 
Log daidzein 0.993 - - - - - 
Log glycitein 0.976 0.963 - - - - 
Log secoisolariciresinol 0.211 0.204 0.300 - - - 
Log total isoflavones 0.999 0.995 0.980 0.227 - - 
Log total lignans 0.208 0.202 0.295 0.994 0.224 - 
Log total phytoestrogens 0.962 0.949 0.963 0.384 0.968 0.381 
Table 4 Multivariate regression model for each phytoestrogen and variables included in the final model for evaluable participants with complete data (n=1797).  
 
 
Abbreviations: CI, confidence interval; Coef., regression coefficient; p, p-value; t, t statistic. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Log genistein  Log daidzein  Log glycitein  Log secoisolariciresinol 
Variable Category Coef. t p 95% CI  Coef. t p 95% CI  Coef. t p 95% CI  Coef. t p 95% CI 
Age at 
menarche  
Years       
 
 
      
 
 
 
      
 
 
 
-0.017 -2.9 0.004 (-0.028 – -0.006) 
Age at 
diagnosis 
Years -0.008 -2.5 0.012 (-0.014 – -0.002) 
 
-0.008 -3.3 0.001 (-0.013 – -0.003) 
 
-0.009 -4.0 <0.001 (-0.014 – -0.005) 
 
0.003 3.1 0.002 (0.001 – 0.005) 
BMI at 
diagnosis 
Kg/m2       
 
 
      
 
 
 
      
 
 
 
-0.004 -2.4 0.018 (-0.008 – -0.001) 
Parity  0 
    
 
    
 
    
 Ref. 
   
 1+     
  
 
    
 
    
 -0.102 -3.4 0.001 (-0.160 – -0.043) 
Breast 
feeding 
No Ref. 
   
 Ref. 
   
 Ref. 
   
 Ref. 
   
Yes 0.144 2.8 0.005 (0.043 – 0.244)  0.145 3.0 0.003 (0.051 – 0.239)  0.129 2.9 0.004 (0.042 –  0.215)  0.090 4.5 <0.001 (0.050 – 0.130) 
HRT No Ref. 
   
 
    
 
    
 
    
 Yes -0.117 -2.0 0.048 (-0.234 – -0.001)    
   
 
    
 
    
Supplement 
use  
No Ref. 
   
 Ref. 
   
 Ref. 
   
 Ref. 
   
Yes 0.156 3.1 0.002 (0.056 – 0.256)  0.135 2.8 0.005 (0.042 – 0.228)  0.159 3.6 <0.001 (0.074 –  0.245)  0.067 3.8 <0.001 (0.032 –  0.102) 
Smoking  Non-smoker Ref. 
   
 Ref. 
   
 Ref. 
   
 Ref. 
   
Smoker -0.247 -2.7 0.006 (-0.423 – -0.070)  -0.259 -3.1 0.002 (-0.424 – -0.094)  -0.247 -3.2 0.001 (-0.399 – -0.095)  0.014 0.5 0.650 (-0.047 – 0.076) 
Ex-smoker -0.027 -0.5 0.607 (-0.132 –  0.077)  -0.049 -1.0 0.324 (-0.147 – 0.049)  -0.023 -0.5 0.622 (-0.113 –  0.067)  0.048 2.6 0.010 (0.012 – 0.085) 
Table 5 Average daily portions and phytoestrogen intake consumed for the different food groups by 
age tertile. 
 
 
Age tertile 
1 2 3 
Age (years) mean 43.4  ±  4.50 54.0  ±  2.80 64.2  ±  3.90 
                    range 27.0  –  49.5 49.5  –  58.7 58.7  –  75.3 
    
Food Groups  Mean number of portions per day ± SD 
Meat 1.22  ±  1.13 1.08  ±  0.63 1.17  ±  0.75 
Fish  0.36  ±  0.28 0.35  ±  0.28 0.39  ±  0.27 
Bread and savoury biscuits 1.92  ±  1.40 2.11  ±  1.62 2.18  ±  1.56 
Cereals  0.69  ±  0.56 0.71  ±  0.52 0.78  ±  0.64 
Potatoes, rice and pasta 1.27  ±  0.49 1.14  ±  0.48 1.13  ±  0.48 
Dairy products and fats 3.26  ±  1.97 3.18  ±  1.66 3.31  ±  1.87 
Sweets and snacks 3.78  ±  3.54 3.20  ±  2.97 3.09  ±  3.00 
Soups, sauces and spreads 1.16  ±  0.88 1.21  ±  1.02 1.27  ±  0.95 
Non-alcoholic drinks  6.13  ±  2.54 6.17  ±  2.49 5.94  ±  2.49 
Alcoholic drinks  0.84  ±  1.04 0.88  ±  1.13 0.78  ±  0.99 
Fruit  2.50  ±  2.12 3.03  ±  2.41 3.26  ±  2.61 
Vegetables  4.36  ±  2.15 4.65  ±  2.27 4.82  ±  2.38 
Beans, lentils, nuts and peas 0.34  ±  0.40 0.36  ±  0.44 0.31  ±  0.39 
Tofu, soya meat, TVP and 
vegeburgers 
0.03  ±  0.12 0.03  ±  0.11 0.01  ±  0.05 
    
Phytoestrogen 
consumption µg/d 
Geometric mean 
(95% CI) 
Geometric mean 
(95% CI) 
Geometric mean 
(95% CI) 
Total isoflavones 522.1   (480.1 – 567.9) 502.2   (460.0 – 548.2) 433.1   (404.1 – 464.2) 
Total lignans 309.2   (299.6 – 319.1) 330.2   (321.0 – 339.7) 329.0   (320.3 – 337.9) 
Total phytoestrogens 957.3   (897.8 – 1020.7) 966.3   (905.2 – 1031.6) 853.4   (811.3 – 897.7) 
 
Abbreviations: CI, confidence intervals; SD, standard deviation; TVP, textured vegetable protein. 
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Fig. 1 
 
Figure
Excluded 
Recruited       n=3390 
Eligible patients    n=3159 
 Not eligible                                              n=231 
 Bilateral breast cancer                             n=2 
 DCIS only                                              n=11 
 Metastasis at diagnosis                            n=3 
 Previous cancer                                      n=5 
 Recruited outside 9-15 month window        n=204 
 Treatment not finished at recruitment         n=5 
 Ungradable <1mm microinvasion              n=1 
 Completed phase1      n=428 
 FFQ1                n=340;  79.4% 
 GHQ1               n=335;  78.3% 
 Urine sample1          n=338;  79.0% 
 Blood sample1         n=301;  70.3% 
Year 1 Recruitment 
18 months1 
 Completed phase       n=2959 
 Lifestyle questionnaire2  n=2237;  87.9% 
 FFQ                n=2584;  87.3% 
 GHQ                n=2561;  86.5% 
 Food diary            n=2429;  82.1% 
 Urine sample          n=2670;  90.2% 
 Blood sample          n=2397;  81.0% 
Year 2 
 Lifestyle questionnaire   n=2992;  94.7% 
 Pre-diagnosis FFQ      n=2704;  85.6% 
 Post-diagnosis FFQ     n=2914;  92.2% 
 GHQ                n=2940;  93.1% 
 Urine sample          n=3115;  98.6% 
 Blood sample          n=2955;  93.5% 
 Completed phase       n=2788 
 Lifestyle questionnaire    n=2427;  87.1% 
 FFQ                n=2426;  87.0% 
 GHQ                n=2399;  86.0% 
 Urine sample2          n=2084;  86.5% 
 Blood sample2         n=1845;  76.6% 
Year 3 
 Withdrawn / lost to follow up1   n=23 
 All mortality1               n=0 
 Mortality from breast cancer1   n=0 
 
 Withdrawn / lost to follow up    n=165 
 All mortality               n=35 
 Mortality from breast cancer    n=22  
 
 Withdrawn / lost to follow up   n=280 
 All mortality               n=91 
 Mortality from breast cancer    n=70  
 
Fig. 2 
 
1Recruitment 1998-2004, 2recruitment 2004-2010. Percentages are from active patients at each stage. Data is shown 
up to for all completed visits (up to year 3). Follow-up is still on-going. 
Fig. 3 
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